Introduction {#s1}
============

In many studies, putative cardiac-resident stem and progenitor cells were isolated based on the expression of hematopoietic stem cell (HSC) markers, such as CD34, stem cell antigen-1 (Sca-1), and *c*-kit/CD117 ([@B1]--[@B3]). However, no single cell surface marker definitely identifies a specific entity of cardiac stem cells ([@B4]). Therefore, "functional" stem cell markers have been intensively searched for. It has been proposed that, irrespective of their lineage origin, stem cells may respond in similar ways to regulate self-renewal and differentiation, and that putative "stemness" genes may serve as universal stem cell markers ([@B5]). A widely used universal stem cell marker is aldehyde dehydrogenase (ALDH) ([@B6]--[@B8]). In tunicates, few pluripotential cells with high ALDH enzymatic activity (ALDH^hi^) were able to give rise to all somatic and reproductive cell lineages ([@B9]).

ALDH is a generic designation for a superfamily of NAD-dependent enzymes that catalyze the oxidation of aldehydes to acids. The ALDH family includes 19 members in human, which share some amino acid sequence similarity and certain functions while differing in intracellular localization, tissue distribution, and substrate specificity. ALDHs are localized in the cytoplasm, mitochondria or nucleus and participate in many biological processes including the detoxification of exogenous aldehydes and the metabolism of vitamin A, alcohol and reactive oxygen species (ROS) ([@B7], [@B10]). ALDH1A1 is a detoxifying enzyme responsible for oxidizing aldehydes to carboxylic acids ([@B11]). High-level ALDH1A1 expression regulates self-renewal and differentiation in HSCs and neural stem cells ([@B12]--[@B14]). ALDH1A1 has been implicated in chemotherapeutic resistance of HSCs via metabolization and detoxification of chemotherapeutics like cyclophosphamide ([@B15]). ALDH1A is the rate-limiting factor in the production of retinoic acid (RA) via oxidation of *all-trans* retinal and 9-cis-retinal ([@B16]--[@B18]). RA activates nuclear RA receptors (RARs) that control the transcription of genes with RA response elements (RAREs) in their promoters, thereby regulating stem cell functions ([@B13], [@B19]). Elevated activity of additional ALDH isoforms, namely ALDH1A2, ALDH1A3, ALDH1A7, ALDH2^\*^2, ALDH3A1, ALDH4A1, ALDH5A1, ALDH6, and ALDH9A1, has been observed in normal and cancer stem cells ([@B10], [@B20]--[@B25]). It has been proposed that the role of ALDH as a stem cell marker may come down to the specific isoform(s) expressed ([@B20]). Thus, ALDH not only may be considered a stem cell marker, but also may well play functional roles in terms of self-renewal, differentiation, and/or expansion. It should be noted, however, that currently available commercial assays identifying ALDH^hi^ cells as those actively metabolizing BODIPY-aminoacetaldehyde (Aldefluor®) ([@B26]) do not distinguish the specific ALDH isoforms ([@B8]).

In human, ALDH expression by HSCs has been evaluated as a predictor of hematopoietic recovery after peripheral stem cell mobilization ([@B27]) and a biomarker for umbilical cord blood potency ([@B28]). Both bone marrow and cord blood-derived ALDH^hi^ cells have shown therapeutic potential in limb ischemia ([@B29]) and myocardial infarction models ([@B30]). In clinical trials, autologous bone marrow-derived ALDH^hi^ cells did not improve functional or magnetic resonance outcomes in patients with peripheral artery disease ([@B31]). More encouraging results were reported in patients with ischemic heart failure ([@B32]). We were the first to isolate cardiac atrial appendage-derived progenitor cells based on ALDH activity ([@B33], [@B34]). Koninckx et al. ([@B35]) then reported that human ALDH^hi^ cardiac atrial appendage stem cells (CASC) gave rise to cardiac cells and improved cardiac function upon injection into infarcted pig hearts. However, this study did not compare ALDH^hi^ and ALDH^lo^ cells nor did it define the specific ALDH isoform(s) expressed and their functional roles.

The present study aimed to compare human ALDH^hi^ and ALDH^lo^ atrial appendage cells both phenotypically and functionally, and to identify the specific ALDH isoform(s) expressed. ALDH1A3 was found to be the key isoform responsible for Aldefluor positivity in ALDH^hi^ cells. Gain- and loss-of-function experiments revealed a role for ALDH1A3 in cell proliferation.

Materials and methods {#s2}
=====================

Cell isolation and flow cytometric analysis
-------------------------------------------

Human right atrial appendage specimens were obtained from male and female patients (29--91 years old) who underwent cardiac surgery for ischemic and/or valvular heart disease through donation. The protocol received authorization from the University Hospital Ethics Committee and the Cantonal Ethics Committee Ethics Committee of Canton Vaud, Switzerland on research involving humans. Informed, written consent was obtained from the participants. In 3 patients (76--86 years old) who underwent left ventricular (LV) assist device implantation, tissue specimens were obtained from the LV apex. Immediately after their procurement, tissue specimens were kept on ice, minced, and digested in a buffer containing 0.45 mg/ml collagenase from Clostridium histolyticum and 0.1 mg/ml proteinase bacterial Type XXIV (both from Sigma Aldrich, St. Louis, MO, USA). Four rounds of enzymatic digestion were used. Freshly isolated cells were immediately reacted with Aldefluor (Stem Cell Technologies, Vancouver, BC, Canada) to identify ALDH^hi^ cells. Briefly, 2 × 10^6^ cells/mL were suspended in Aldefluor assay buffer containing the ALDH substrate BODIPYaminoacetaldehyde and incubated at 37°C for 45 min. For each sample, cell aliquots were incubated with or without 50 mM diethylaminobenzaldehyde (DEAB), an ALDH-specific inhibitor ([@B36]), and analyzed on a Gallios flow cytometer (Beckman Coulter, Indianapolis, IN, USA). The threshold used for the ALDH^hi^ gate was 2.0% of DEAB-treated control cells. Dead cells and cells in the early-mid apoptosis were identified using DAPI and Annexin V apoptosis detection kit-APC (eBioscience; Thermo Fisher Scientific, Waltham, MA, USA), respectively. For flow cytometric analyses of surface marker expression, 1 × 10^5^ cells/tube were incubated with Aldefluor and subsequently stained with marker-specific antibodies (Supplementary Table [1](#SM1){ref-type="supplementary-material"}) for 30 min in the dark. Fluorescence-activated cell sorting (FACS) based on ALDH activity was performed on a MoFloAstrios cell sorter (Beckman Coulter). To prevent cross-contamination between ALDH^hi^ and ALDH^hi^ cells, sorting gates of these 2 populations were set up at least one log apart. The purity of sorted populations was reanalyzed using ALDH^hi^ and ALDH^lo^ cells and was shown to be greater than 95%. For expansion, cells were plated in gelatin-coated 6-well plates and cultured in expansion medium (3:1 DMEM 1g/l glucose/Medium 199 \[Invitrogen, Carlsbad, CA, USA\] supplemented with 10% horse serum \[Serotec; BioRad Labs., Hercules, CA, USA\], 5% fetal calf serum (FCS) \[Serotec\], 100 U/ml penicillin \[Invitrogen\], and 100 mg/ml streptomycin \[Invitrogen\]). Cells that remained in suspension after 24 h in culture were discarded, and adherent cells were expanded. In a subset of experiments, atrial appendage specimens were not dissociated using enzymatic techniques, but cultured *ex vivo* as primary tissue explants ([@B37]). Briefly, atrial tissue explants were cut into small pieces (≈1 mg) that were placed in gelatin-coated culture dishes (Corning; Thermo Fisher Scientific) and cultured in IMDM supplemented with 20% FCS, 100 U/ml penicillin and 100 mg/ml streptomycin. After 10 days, the small pieces of tissue were removed from culture dishes and the cell populations that had migrated out of them (outgrowth cells) were expanded.

Immunocytochemistry
-------------------

Immunocytochemical staining was performed on cells cultured in gelatin-coated wells using the antibodies listed in Supplementary Table [2](#SM2){ref-type="supplementary-material"}. Stained cells were mounted with Vectashield mounting medium containing DAPI (Vector Labs, Burlingame, CA, USA). Images were captured using an Axiovision (Carl Zeiss Jena, Germany) fluorescence microscope and a Nikon LSR Eclipse TE2000S inverted fluorescence microscope (Nikon, Tokyo, Japan).

Clonogenicity and cell proliferation assays
-------------------------------------------

To assess clonogenicity, atrial cells were seeded at limit dilution and single cells were identified under a light microscope. Clones derived from single cells were counted at later time points. To assess cell growth, cell numbers were counted at different time points after plating. The effect of DEAB on proliferation was assessed in outgrowth cells. Cell proliferation was measured using Click-iT® EdU Alexa Fluor® 488 imaging kit (Invitrogen), as per manufacturer\'s instructions. Briefly, cells were incubated with EdU (10 μM final concentration) for 2 h in expansion medium, fixed with paraformaldehyde 2%, permeabilized with 0.3% Triton, incubated with Alexafluor azide for 30 min in the dark, and mounted with Vectashield. EdU^+^ cells and total cells were counted under a fluorescence microscope, and percentages of EdU^+^ cells were calculated. Cell density was expressed using a microscopic score (range: 0--4) assigned by two independent investigators blind to experimental conditions. RA levels in cells were measured using Human Retinoic Acid ELISA Kit (MBS705877-96; ANAWA Biotrend, Wangen, Switzerland). The ability of the RA receptor agonist all*-trans* RA to replace ALDH in promoting cell growth was tested. Varying concentrations of all*-trans* RA (Sigma) were added to explant outgrowths cultured in the presence of 100 μM DEAB, and cell density was assessed under a light microscope.

RNA isolation, reverse transcription, and real-time PCR
-------------------------------------------------------

Total RNA was extracted using RNeasy isolation kit (Qiagen N V, Hilden, Germany). Reverse transcription was performed with QuantiTect Whole Transcriptome Kit (Qiagen) for RNA from freshly isolated cells, and with Verso cDNA Synthesis Kit (Thermo Fisher) for RNA from culture-expanded cells. For expression analyses of cardiac transcription factors, pluripotency-associated genes and cardiac differentiation markers, cDNA was used as a template for real-time PCR or relative quantitative PCR (qPCR) using specific probes and the ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher). For expression analyses of ALDH isoforms, Fast SYBR®Green Master Mix (Life Technologies; Thermo Fisher) with gene-specific primers (Thermo Fisher; Supplementary Table [3](#SM3){ref-type="supplementary-material"}) were used. Each reaction was carried out in triplicate. To calculate the relative expression levels, we used the 2^−ΔΔCt^-method. RPL27 mRNA was used as an endogenous control. Experiments linked to differentiation were done with Taqman probes using β2--microglobuline as a reference gene.

Western blotting
----------------

Western blotting was performed on ALDH^hi^ and ALDH^lo^ sorted cells using rabbit anti-human ALDH1A3 antibody (Ab 129815, Abcam, Cambridge, UK).

Cardiomyogenic differentiation
------------------------------

Atrial cells at culture-passage 2 were reacted with Aldefluor. ALDH^hi^ and ALDH^lo^ populations were sorted. Two protocols were used to induce cardiac differentiation. Using the first protocol (no NOTCH modulation), differentiation was induced by switching the cells to MEM alpha (Invitrogen) containing 2% horse serum, 1 mmol/l dexamethasone (Sigma-Aldrich), 50 mg/ml ascorbic acid (Sigma-Aldrich), 10 mmol/l b-glycerophosphate (Sigma-Aldrich), 100 U/ml penicillin, and 100 mg/ml streptomycin (differentiation medium). Because cells were spontaneously differentiating into smooth muscle cells using this protocol, a recently developed protocol involving sequential NOTCH activation and inhibition was applied ([@B38]). Cells were cultured on immobilized Delta-like1 (DLL1) ligand (R&D Systems, Minneapolis, MN, USA) during 24 h. After cell re-suspension, NOTCH pathway was inhibited by the inhibitor of gamma secretase, DAPT (Sigma-Aldrich). Cells were cultured under those conditions for 3 weeks in differentiation medium, and cells were then assessed for expression of cardiac-specific (Myh6, Myh7) and smooth muscle (SM)-specific (Myh11) genes using quantitative RT-PCR. Expression of cardiac-specific α-actinin and troponin I (cTnI), as well as SM myosin heavy chain (sm-MHC) was assessed immunocytochemically. Cells positive for α-actinin or cTnI, or both markers, and total cells were counted under the fluorescence microscope. Percentages of positive cells were calculated.

siRNA silencing
---------------

Small interfering RNA (siRNA) was used to knockdown ALDH isoform expression in atrial cells. All siRNAs were obtained from Thermo Fisher. ALDH^hi^ sorted cells seeded on 6 well-plates (50.000 cells/well) were allowed to adhere overnight. Transfection was performed with Lipofectamine RNAiMAX (Invitrogen), as per manufacturer\'s instructions. siALDH1A3 was tested at different concentrations. In subsequent experiments, siRNA specific for ALDH isoforms 1A1, 1A2, 1A3, 2A, 4A1, 8A1 was used at the 10 nM concentration. Percentages of ALDH^hi^ cells were measured at 24 h post-transfection using the Aldefluor assay. EdU was added to cells at 24 h post-transfection, and EdU incorporation was assessed using Click-iT® EdU Alexa Fluor® 488 imaging kit.

ALDH1A1 and ALDH1A3 overexpression
----------------------------------

The retroviral vector pMSCVpuro with either ALDH1A1 or ALDH1A3 coding sequences inserted was described and validated previously ([@B32]). A retroviral vector with no insert was used to control for unspecific virus-related effects. ALDH^lo^ sorted cells were transduced with retroviral supernatants in 6-well plates (50,000 cells/well), as described previously ([@B32]). Twenty-four hours post-transduction, cells were passaged and seeded at ≈50% density. EdU was added to the cells 24 h later. Cell proliferation was analyzed using Click-iT® EdU Alexa Fluor® 488 imaging kit.

Statistics
----------

The data are presented as mean ± S.D. Student *t*-test was used to compare two normally distributed populations. The Mann-Whithney U test was used for nonparametric comparisons of two groups. Differences with probability values *p* \< 0.05 were considered statistically significant.

Results {#s3}
=======

Identification of ALDH^hi^ cells
--------------------------------

Freshly isolated, myocyte-depleted populations were isolated based on ALDH activity using the Aldefluor assay. ALDH^hi^ gating was established by inhibiting ALDH activity using DEAB (Figure [1A](#F1){ref-type="fig"}). Freshly isolated cells from right atrial appendages contained an average of 21.5 + 12.4% ALDH^hi^ cells (*n* = 86). In a few LV apex specimens available (*n* = 3), ALDH^hi^ cells averaged 12.3 ± 2.1% of total cells. This finding demonstrated that the LV apex also contains ALDH^hi^ cells; however, quantitative comparisons of atrial and LV cells were not performed due to the small LV sample size. A majority of ALDH^hi^ atrial cells (73.1 + 20.2%) expressed the primitive surface marker CD34 (Figure [1B](#F1){ref-type="fig"}), which was confirmed immunocytochemically (Figure [1C](#F1){ref-type="fig"}), but not CD45 (\<5%). There was no significant correlation between ALDH^hi^ cell number and age (Figure [1D](#F1){ref-type="fig"}), gender, or ischemic vs. heart valve disease (data not shown). Because freshly isolated ALDH^lo^ cells could not be expanded *ex vivo*, we used ALDH^lo^ outgrowth cells ([@B37]) in a subset of experiments including direct comparisons with ALDH^hi^ cells. In addition, outgrowth cells are of translational interest, as they give rise to cardiosphere-derived cells that have been tested clinically in patients after myocardial infarction ([@B39]). Representative gating sequences from FACS experiments with different populations, namely freshly isolated atrial cells, freshly isolated LV cells, expanded atrial cells, and outgrowth cells are shown in Figure [1E](#F1){ref-type="fig"}. In freshly isolated cells, but not in expanded ones and outgrowth cells, ALDH^hi^ and ALDH^lo^ cells were visualized as discrete populations, and the Aldefluor signal was incompletely inhibited by DEAB. By contrast, the Aldefluor signal was fully suppressed by DEAB in both expanded and outgrowth cells. These results suggest that ALDH activity in freshly isolated cells may be higher than in expanded and outgrowth cells. The frequency of ALDH^hi^ cells within the outgrowth population was stable during 3 weeks but decreased thereafter (Figure [1F](#F1){ref-type="fig"}), suggesting that the pool of ALDH^hi^ cells within cultured tissue explants may be exhausted at late time points.

![Flow cytometry analysis of ALDH^hi^ atrial cells. **(A)** Freshly isolated cells. ALDH^hi^ gating was established by inhibiting ALDH activity in Aldefluor-reacted cells with DEAB. Left panels: ALDH/side scatter (SSC-A) plots. Right panels: ALDH/forward scatter (FSC-A) plots. **(B)** Freshly isolated cells. Aldefluor activity and CD34 expression. **(C)** CD34 immunostaining (red); ALDH (green); staining with istotype-matched control antibody is shown. **(D)** ALDH^hi^ cells (%) did not correlate with age. **(E)** FACS plots of different populations (top to bottom: freshly isolated atrial cells, freshly isolated LV cells, expanded atrial cells, atrial outgrowth cells). Gating sequences are shown. R1-gated cells in FSC-A/SSC-A plots are gated for homogeneity (R2, R3) and DAPI exclusion (R4). R5 and R7 gates define ALDH^lo^ and ALDH^hi^ cells, respectively. To prevent cross-contamination between ALDH^hi^ and ALDH^hi^ cells, R5 and R7 gates were set one log apart (i.e., R6-gated cells were discarded). **(F)** Percentages of ALDH^hi^ outgrowth cells after 1--4 weeks of *ex vivo* tissue culture.](fcvm-05-00090-g0001){#F1}

Freshly isolated ALDH^hi^ cells express CD34 along with mesenchymal and endothelial markers
-------------------------------------------------------------------------------------------

Differential surface marker expression in ALDH^hi^ and ALDH^lo^ atrial cells has not been analyzed previously. Freshly isolated ALDH^hi^ cells (Figure [2A](#F2){ref-type="fig"}) expressed the primitive marker CD34, platelet endothelial cell adhesion molecule-1 (PECAM-1)/CD31, and endoglin/CD105, a marker expressed by both endothelial and stromal progenitor cells. Thus, the ALDH^hi^ population appeared to include both mesenchymal progenitors and differentiating endothelial progenitors. The ALDH^hi^ population was enriched with cells expressing vascular cell adhesion molecule-1 (VCAM-1)/CD106 (38-fold increase). Small cell subsets expressed the common leukocyte antigen CD45 (\<5%) and stem cell markers *c*-kit/CD117 (1.2 ± 0.9%) and prominin/CD133 (2.3 ± 3.1%). ALDH^hi^ outgrowth cells lacked CD34 expression. Their surface marker profile did not significantly differ from that of ALDH^lo^ cells (Figure [2B](#F2){ref-type="fig"}).

![Flow cytometry analyses of cell-surface marker expression in ALDH^hi^ and ALDH^lo^ atrial cells. **(A)** Freshly isolated cells. Aldefluor-reacted cells were stained with antibodies to the indicated markers (see Supplementary Table [1](#SM1){ref-type="supplementary-material"}). CD31^+^, CD105^+^, CD34^+^, and CD106^+^ cells (%) are significantly increased in ALDH^hi^ cells relative to ALDH^lo^ cells (fold-increases are indicated); \**p* \< 0.05. **(B)** Outgrowth cells. ALDH^hi^ cells lack CD34 expression and exhibit a marker profile similar to that of ALDH^lo^ cells (*n* ≥ 5 per marker and group).](fcvm-05-00090-g0002){#F2}

Differential expression of pluripotency genes and markers for cardiac lineages
------------------------------------------------------------------------------

We analyzed expression of pluripotency-associated genes and cardiac-specific markers as evidence of presence of primitive cells and cardiac progenitor cells, respectively, in atrial cell populations. Freshly isolated ALDH^hi^ cells expressed pluripotency-associated genes (Oct4, Nanog) and cardiac-specific transcription factors (Nkx2.5, Mef2c, GATA4, Tbx5) at higher levels (3--5 orders of magnitude) than did ALDH^lo^ cells (Figure [3A](#F3){ref-type="fig"}). Nkx2.5, GATA4, and Mef2c expression was confirmed immunocytochemically (Figure [3C](#F3){ref-type="fig"}). Similar albeit weaker differences (1--2 orders of magnitude) were found between ALDH^hi^ and ALDH^lo^ outgrowth cells (Figure [3B](#F3){ref-type="fig"}). These results suggest that the freshly isolated ALDH^hi^ population may be enriched with primitive cells and cells committed to a cardiac fate.

![Expression of pluripotency-associated genes (Oct4, Nanog) and cardiac-specific transcription factors (Nkx2.5, Mef2c, GATA4, Tbx5). **(A)** Quantitative RT-PCR analyses of freshly isolated atrial cells (*n* = 5/group). **(B)** Outgrowth cells (*n* = 5/group). 2^−ΔΔCt^ values for ALDH^hi^ vs. ALDH^lo^ cells are shown. **(C)**. Freshly isolated ALDH^hi^ cells. Immunostaining for Nkx2.5 (red), GATA4 (green), and Mef2c (green); DAPI nuclear counterstaining (blue). Nkx2.5/GATA4 and Nkx2.5/Mef2c double stainings are shown.](fcvm-05-00090-g0003){#F3}

Freshly isolated ALDH^hi^ cells are clonogenic and selectively expandable
-------------------------------------------------------------------------

Freshly isolated ALDH^hi^ cells selectively formed clones and could be expanded *ex vivo*. In principle, this might be due to selective resistance to apoptosis induced by the isolation procedure. After DAPI exclusion, virtually no ALDH^hi^ cells but part of the ALDH^lo^ population were Annexin V-positive (Figure [4A](#F4){ref-type="fig"}) suggesting they were in the early-mid apoptosis. The clonogenicity index was 0.27 ± 0.09% in ALDH^hi^ cells, 0% in ALDH^lo^ cells, and 0.03 ± 0.01% in the bulk (unsorted) population (Figure [4B](#F4){ref-type="fig"}). Freshly isolated ALDH^hi^ cells grew faster than the bulk population. Similarly, ALDH^hi^ outgrowth cells grew faster than ALDH^lo^ ones (Figure [4C](#F4){ref-type="fig"}). Expanded ALDH^hi^ cells lost ALDH activity over time (e.g., the frequency of ALDH^hi^ cells in the progeny of freshly isolated ALDH^hi^ cells after 13 culture-passages was 32%). These observations suggest that high ALDH activity may be required for the initial survival and growth of freshly isolated cells, but not in established cell cultures, reflecting cell adaptation to *in vitro* conditions.

![Cell viability, clonogenicity, cell growth, intracellular RA levels, effects of DEAB and all*-trans* RA. **(A)** Freshly isolated cells. Flow cytometry analysis of DAPI, Aldefluor (with and without DEAB), and Annexin V (right panel). Part of ALDH^lo^ cells are Annexin V-positive (K-+). **(B)** Freshly isolated ALDH^hi^ cells and unsorted cells. Clonogenic analysis (*n* = 3/group). **(C)** *In vitro* growth kinetics. Left panel: freshly isolated cells; right panel: outgrowth cells (*n* = 3/group in both panels). **(D)** Dose-dependent effects of DEAB on EdU incorporation and cell density. **(E)** RA concentrations in ALDH^hi^ and ALDH^lo^ cells measured by ELISA. **(F)** Dose-dependent effects of all*-trans* RA (ATRA) on cell density in the presence of DEAB (100 μM).](fcvm-05-00090-g0004){#F4}

All-*trans* RA reverses DEAB-mediated cell growth suppression
-------------------------------------------------------------

To assess the effect of ALDH on cell growth, explant outgrowths were cultured with or without DEAB at varying concentrations. DEAB reduced proliferation in outgrowth cells in a dose-dependent manner (Figure [4D](#F4){ref-type="fig"}), as determined using an EdU incorporation assay. Because ALDH1 naturally synthesizes RA, we measured RA concentrations in ALDH^hi^ and ALDH^lo^ cells. Not surprisingly, we found higher RA levels in the former (Figure [4E](#F4){ref-type="fig"}). We then tested the ability of all*-trans* RA to replace ALDH in promoting cell growth. all*-trans* RA (10 μM) reversed cell growth suppression mediated by DEAB (Figure [4F](#F4){ref-type="fig"}). These results suggest that ALDH might promote atrial cell growth through RA, at least in part.

ALDH^hi^ cells have higher propensity to produce mature cardiomyocytes than ALDH^lo^ cells
------------------------------------------------------------------------------------------

Having shown that the ALDH^hi^ population is enriched with stem/progenitor cells, we addressed its cardiomyogenic potential. Two differentiation protocols, with or without Notch modulation, were used. Under differentiation conditions with no Notch-modulation, both ALDH^hi^ and ALDH^lo^ cells expressed marked levels of MYH11 gene, while the cardiomyocyte markers MYH6 and MYH7 were not induced (Figure [5A](#F5){ref-type="fig"}). Both populations massively differentiated into smooth muscle cells, as illustrated by smMHC immunostaining; less than 2% of cells stained positive for cardiomyocyte-specific marker α-actinin (Figure [5B](#F5){ref-type="fig"}). By contrast, under Notch-modulated conditions both ALDH^lo^ and ALDH^hi^ cells expressed significant levels of cardiomyocyte-specific MYH6 and MYH7 (Figure [5A](#F5){ref-type="fig"}) and α-actinin (Figures [5B,D](#F5){ref-type="fig"}). Cardiac troponin-I (TNNI) was also identified in differentiated cells. Interestingly, under Notch-modulated conditions MYH6 and MYH7 gene expression was more pronounced in ALDH^hi^ than ALDH^lo^ cells. Similarly, the number of α-actinin/TNNI double positive cells derived from ALDH^hi^ cells was significantly higher than that derived from ALDH^lo^ cells (Figures [5C,D](#F5){ref-type="fig"}). These results indicated that the differentiated ALDH^hi^ cells were more terminally differentiated than ALDH^lo^ cells, consistent with a higher propensity of ALDH^hi^ cells to differentiate into cardiomyocytes.

![Cardiac differentiation of ALDH^hi^ and ALDH^lo^ atrial cells using a Notch modulation-based protocol. **(A)** real-time RT-PCR expression analyses of cardiac-specific (*Myh6, Myh7*) and smooth muscle-specific genes (*Myh11*) under expansion (Exp) and differentiation conditions, with or without Notch modulation. 2^−ΔCt^values are shown. One example of two independent experiments performed in triplicates is shown; \**p* \< 0.05 vs. cells in expansion or between the indicated conditions. **(B)** Immunostaining of ALDH^hi^ and ALDH^lo^ cells for smooth musche-myosin heavy chain (smMHC) and cardiac-specific α-actinin, with or without Notch modulation. **(C)** Immunostaining of ALDH^hi^ and ALDH^lo^ cells for cardiac-specific α-actinin and troponin I (cTNNI) under Notch-modulated conditions. **(D)** Quantitative analyses of smMHC, α-actinin, and α-actinin/cTNNI positive cells; \**p* \< 0.05 vs. cells in expansion (a minimum of 2000 cells in 30 different fields at 40x magnification were analyzed for quantification).](fcvm-05-00090-g0005){#F5}

ALDH1A3 is the most highly expressed ALDH isoform in atrial cells
-----------------------------------------------------------------

The specific ALDH isoforms expressed in ALDH^hi^ atrial cells have not been identified previously. We therefore analyzed the ALDH isoform expression profiles of ALDH^hi^ and ALDH^lo^ cells. ALDH1A3 was the most highly expressed isoform in freshly isolated ALDH^hi^ cells, as well as the most highly overexpressed isoform in ALDH^hi^ relative to ALDH^lo^ cells (≈8-fold increase; Figure [6A](#F6){ref-type="fig"}). ALDH1A3 protein levels in ALDH^hi^ cells were higher than in ALDH^lo^ cells, as evidenced by Western blot analysis (Figure [6B](#F6){ref-type="fig"}). Similar findings were observed in outgrowth cells (≈6-fold increase in ALDH1A3 mRNA levels in ALDH^hi^ vs. ALDH^lo^ cells; Figure [6C](#F6){ref-type="fig"}). For comparison, a subset of 10 ALDH isoforms selected based on published data ([@B40]) were measured in atrial total tissue, and ALDH2 was found to be the most highly expressed isoform (Figure [6D](#F6){ref-type="fig"}). Thus, ALDH1A3 is the key isoform expressed in ALDH^hi^ atrial cells.

![RT-PCR analysis of *ALDH* isoform gene expression in different populations. **(A)** ALDH^hi^ cells isolated using enzymatic techniques. Upper panel: ALDH isoform expression (2^−ΔCt^ values; *n* = 4 patients). Lower panel: Relative expression in ALDH^hi^ vs. ALDH^lo^ cells (2^−ΔΔCt^ values; *n* = 4). **(B)** Western blot showing ALDH1A3 protein expression in unsorted, ALDH^hi^ and ALDH^lo^ atrial cells. **(C)** Outgrowth cells. Relative expression in ALDH^hi^ vs. ALDH^lo^ cells is shown (*n* = 3). **(D)** Total atrial tissue (2^−ΔCt^ values; *n* = 3). ND, not determined (2^−ΔΔCt^ values that could not be calculated).](fcvm-05-00090-g0006){#F6}

ALDH1A3 siRNA reduces ALDH activity and *in vitro* cell proliferation
---------------------------------------------------------------------

To address the contributions of individual ALDH isoforms to ALDH activity in ALDH^hi^ cells, we examined whether altering their expression levels would affect ALDH activity. Isoform-specific siRNAs were transfected into ALDH^hi^ sorted cells, which were then analyzed using the Aldefluor assay. siALDH1A3 reduced the percentage of ALDH^hi^ cells in a dose-dependent manner up to ≈90% (Figures [7A,B](#F7){ref-type="fig"}). On the other hand, siALDH1A1, siALDH1A2, siALDH2A, siALDH4A1, and siALDH8A1 (10 nM) did not significantly affect percentages of ALDH^hi^ cells (Figure [7C](#F7){ref-type="fig"}). To address the role of ALDH1A3 in cell proliferation, siALDH1A3 (10 nM) was transfected into ALDH^hi^ sorted cells and proliferation was assessed using EdU incorporation kit. siALDH1A3 reduced the number of EdU^+^ cells by ≈40% (Figure [7D](#F7){ref-type="fig"}).

![ALDH isoform-specific loss- and gain-of-function studies. **(A)** Flow cytometry plots of ALDH^hi^ sorted, Aldefluor-reacted cells (with or w/o DEAB) after siALDH1A3 transfection or mock transfection (no siRNA). **(B)** siALDH1A3 dose-response study. ALDH^hi^ cell numbers after siALDH1A3 transfection using the indicated concentrations relative no siRNA. **(C)** ALDH^hi^ cell numbers after siALDH-isoform-specific transfection (10 nM) relative to no siRNA). **(D)** EdU^+^ cell numbers (%) after siALDH1A3 transfection (10 nM) relative no siRNA. **(E)** Flow cytometry plots of ALDH^lo^ sorted, Aldefluor-reacted cells (with or w/o DEAB) transduced with pMSCVpuro-ALDH1A1 or pMSCVpuro-ALDH1A3 retroviral vectors, or control vector with no insert (pMSCVpuro). **(F)** ALDH^hi^ cell numbers after transduction with pMSCVpuro-ALDH1A1 or pMSCVpuro-ALDH1A3 relative to control vector. **(G)** EdU^+^ cell numbers (%) after transduction with pMSCVpuro-ALDH1A1 or pMSCVpuro-ALDH1A3 relative to control vector; \**p* \< 0.05.](fcvm-05-00090-g0007){#F7}

ALDH1A3 overexpression increases *in vitro* cell proliferation
--------------------------------------------------------------

Having shown that ALDH1A3 knockdown inhibits ALDH^hi^ cell proliferation, we overexpressed this isoform in ALDH^lo^ cells. Retrovirus-mediated ALDH1A3 gene transduction into ALDH^lo^ sorted cells enhanced both ALDH activity (Figures [7E,F](#F7){ref-type="fig"}) and cell proliferation (Figure [7G](#F7){ref-type="fig"}) compared with cells infected with control retrovirus with no insert. ALDH1A1 gene transduction also induced a minor increase in Aldefluor-positive cells. Collectively, these results indicate that ALDH1A3 promotes *in vitro* proliferation of atrial-derived cells.

Discussion {#s4}
==========

We and others have shown previously that high ALDH activity defines a human cardiac atrial appendage cell population enriched with stem and progenitor cells that have cardiomyogenic potential ([@B33], [@B35]). ALDH^hi^ activity coincides with primitive surface marker (CD34^+^) as well as mesenchymal and endothelial progenitor marker expression. Regarding the co-expression of CD34 and CD31, CD34^+^ endothelial progenitor-like cells have been described previously ([@B41]). Interestingly, the ALDH^hi^ population is significantly enriched with VCAM1^+^ cells. Moreover, ALDH^hi^ cells differentially express both pluripotency genes and markers for more established cardiac lineages including Nkx2.5, consistent with them being enriched with both primitive cells and cells committed to a cardiac fate. VCAM1^+^Nkx2.5^+^ cells have been identified previously as a discrete lineage of myocardial committed cells during early human cardiovascular development ([@B42]). These findings raise the question as to whether the VCAM1^+^Nkx2.5^+^ subset of the adult ALDH^hi^ atrial population consists of myocardial committed progenitor cells. These results suggest that ALDH^hi^ atrial cells may be enriched with cells that have cardiomyogenic potential. To address this aspect, we used a novel differentiation protocol based on Notch modulation ([@B38]). Compared with ALDH^lo^ cells, ALDH^hi^ cells produced higher numbers of mature cardiomyocytes, as evidenced by higher expression levels of cardiac specific genes (MYH6, MYH7) and higher frequencies of cardiac-specific α-actinin/troponin I double-positive cells. These results indicate that the ALDH^hi^ population is enriched with cardiac progenitor cells. *In vivo* lineage tracing studies addressing the role of ALDH^hi^ cardiac cells are still needed.

Freshly isolated ALDH^hi^ cells, but not ALDH^lo^ cells, include a subset of clonogenic cells and can be expanded. Annexin V-staining suggests that ALDH^hi^ cells may be more apoptosis-resistant than ALDH^lo^ ones. Higher apoptosis-resistance of ALDH^hi^ vs. ALDH^lo^ cells has been reported in various cancer stem cells ([@B43]--[@B45]). Silencing ALDH1A by siRNA or shRNA in human melanoma cancer stem cells led to cell cycle arrest, apoptosis and decreased cell viability *in vitro* and reduced tumorigenesis *in vivo* ([@B45]). In our study, the theoretical possibility that low ALDH activity in a majority of freshly isolated cells is a result of apoptosis, rather than its cause, cannot be ruled out. Nevertheless, DAPI/Annexin-V double-negative ALDH^lo^ cells that were not in the early-mid apoptosis still failed to grow *in vitro*, suggesting that high ALDH activity might be required in the initial cell culture stages. On the other hand, both the ALDH^lo^ subset of the ALDH^hi^ progeny (i.e., ALDH^hi^ cells having lost their ALDH activity over time *in vitro*) and ALDH^lo^ outgrowth cells could be expanded, albeit with slower growth kinetics compared with ALDH^hi^ cells. This observation suggests that high ALDH activity may not be required in established cell cultures possibly due to cell adaptation mechanisms.

ALDH isoform expression analysis identified ALDH1A3 as both the most highly expressed isoform in ALDH^hi^ atrial cells and the main differentially expressed isoform in ALDH^hi^ vs. ALDH^lo^ cells. Similar results were found in both freshly isolated and outgrowth cells. Moreover, ALDH^hi^ cells showed higher ALDH1A3 protein levels than ALDH^lo^ cells. siALDH1A3 transfected into ALDH^hi^ cells reduced the number of cells that remained ALDH^hi^ by ≈90%, whereas knocking down ALDH1A1, ALDH1A2, ALDH2A, ALDH4A1, or ALDH8A1 did not significantly affect it. These findings establish ALDH1A3 as the key isoform responsible for ALDH activity in ALDH^hi^ cells. siALDH1A3 transfected into ALDH^hi^ cells reduced their proliferation. Specific ALDH inhibition by DEAB likewise suppressed cell proliferation. Conversely, retrovirus-mediated ALDH1A3 gene transduction into ALDH^lo^ cells promoted it. ALDH1A1 overexpression induced a similar albeit weaker effect, suggesting that exogenous ALDH1A1 may replace the naturally expressed ALDH1A3 isoform in this respect.

ALDH1A is the rate-limiting factor in the production of RA ([@B16]--[@B18]). We found higher RA levels in ALDH^hi^ atrial cells than in ALDH^lo^ cells. Moreover, the RA receptor agonist, all*-trans* RA, replaced ALDH in promoting atrial cell growth in the presence of DEAB. In breast cancer cell lines, ALDH1A3 influenced cancer progression via differential RA signaling ([@B44]). In human melanoma cancer stem cells, ALDH1A contributed to the stemness through RA-dependent and -independent pathways ([@B45]). In HSCs, all*-trans* RA reversed DEAB-mediated effects on cell expansion and differentiation, suggesting that the ability of ALDH to generate RA is important in determining HSC fate ([@B13]). Of note, the catalytic activity of ALDH1A3 for all*-trans* retinal may be 10-fold higher than that of ALDH1A1 ([@B46]). Moreover, ALDH1A3 is transcriptionally activated by all*-trans* RA in human epidermal keratinocytes, which raises the theoretical possibility of a positive feedback loop between ALDH1A3 and RA in some cell types ([@B47]). Our results are consistent with, but do not firmly establish, RA-dependent ALDH effects on atrial cell growth.

Functional roles of ALDH1A3 in stem/progenitor cells are poorly understood. ALDH1A3 promotes neural progenitor cell self-renewal through the regulation of ALDH1A3 pre-mRNA 3′-end processing by RNA-binding protein Sam68 (Khdrbs1). Decreases in ALDH1A3 expression and activity resulted in decreased clonogenicity and reduced the pool of proliferating neural progenitor cells ([@B48]). Several studies showed that ALDH1A3 is a cancer stem cell gene. ALDH1A3 expression was detected in 78% of small-sized Ki-67^+^ proliferating progenitor cells in the human breast cancer cell line HCC1937 ([@B43]). Most recently, ALDH1A3 was shown to affect colon cancer *in vitro* proliferation and invasion depending on CXCR4 status ([@B49]). In neuroblastoma cell lines expressing high ALDH1A3 levels, ALDH1A3 knockout via CRISPR/Cas9 gene editing reduced clonogenicity and mediated cell type-dependent inhibition of self-renewal properties of tumor inducing cells ([@B50]). Collectively, these findings indicate that ALDH1A3 play functional roles in both normal and cancer stem/progenitor cells.

In conclusion, our results suggest that the ALDH^hi^ population isolated from human cardiac atrial appendages may be enriched with stem/progenitor cells showing cardiomyogenic potential, and that ALDH1A3 is the key ALDH isoform responsible for ALDH activity in these cells, affecting their *in vitro* proliferation.
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